Advancing mediastinal sampling in non-metastatic lymphadenopathy
Despite advances in PET/CT, tissue confirmation remains essential for mediastinal lymphadenopathy. EBUS-TBNA is minimally invasive but limited by cytology, particularly in benign disease and lymphoma. Emerging EBUS-guided techniques, notably transbronchial mediastinal cryobiopsy, improve diagnostic yield where tissue architecture is required. The multicenter randomized study<sup>1</sup> strengthens evidence for its added value, while underscoring the need for selective application and standardized, indication-specific trials.
Authors
- Reto Engeli
- Thomas Gaisl (ORCID: https://orcid.org/0000-0002-9017-6143)
- Juergen Hetzel
- Carolin Steinack
Institutions
- University Hospital of Basel (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Med
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.medj.2026.101025
- Primary Topic
- Lymphadenopathy Diagnosis and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00